Wall Street analysts expect Intellia Therapeutics, Inc. (NASDAQ:NTLA) to announce sales of $8.60 million for the current quarter, Zacks reports. Eight analysts have issued estimates for Intellia Therapeutics’ earnings, with the highest sales estimate coming in at $15.22 million and the lowest estimate coming in at $4.67 million. Intellia Therapeutics reported sales of $22.22 million during the same quarter last year, which would suggest a negative year over year growth rate of 61.3%. The company is expected to announce its next earnings results on Thursday, November 4th.
According to Zacks, analysts expect that Intellia Therapeutics will report full-year sales of $32.43 million for the current financial year, with estimates ranging from $22.33 million to $49.99 million. For the next financial year, analysts expect that the business will report sales of $43.22 million, with estimates ranging from $22.80 million to $70.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, August 5th. The company reported ($1.01) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.40). The firm had revenue of $6.55 million for the quarter, compared to analysts’ expectations of $12.21 million. Intellia Therapeutics had a negative net margin of 442.58% and a negative return on equity of 39.01%. The firm’s revenue was down 59.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.61) EPS.
In other Intellia Therapeutics news, EVP Laura Sepp-Lorenzino sold 26,000 shares of the stock in a transaction on Wednesday, August 4th. The stock was sold at an average price of $138.24, for a total transaction of $3,594,240.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jean Francois Formela sold 553,376 shares of the stock in a transaction on Monday, June 28th. The shares were sold at an average price of $132.73, for a total value of $73,449,596.48. The disclosure for this sale can be found here. Insiders have sold a total of 833,279 shares of company stock worth $117,165,467 over the last 90 days. 3.90% of the stock is currently owned by company insiders.
Several institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in Intellia Therapeutics during the 2nd quarter worth about $3,928,000. Parametric Portfolio Associates LLC raised its stake in shares of Intellia Therapeutics by 139.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 65,872 shares of the company’s stock valued at $10,665,000 after buying an additional 38,365 shares during the last quarter. Comerica Bank purchased a new position in shares of Intellia Therapeutics during the 2nd quarter valued at about $255,000. Marshall Wace LLP increased its stake in shares of Intellia Therapeutics by 401.3% in the 2nd quarter. Marshall Wace LLP now owns 74,744 shares of the company’s stock valued at $12,101,000 after purchasing an additional 59,835 shares in the last quarter. Finally, Mariner LLC purchased a new position in shares of Intellia Therapeutics in the 2nd quarter valued at about $2,426,000. 84.32% of the stock is owned by hedge funds and other institutional investors.
Shares of NTLA opened at $148.36 on Tuesday. The business has a 50-day simple moving average of $152.46 and a two-hundred day simple moving average of $106.68. The stock has a market cap of $10.90 billion, a price-to-earnings ratio of -51.87 and a beta of 2.14. Intellia Therapeutics has a 52 week low of $18.81 and a 52 week high of $202.73.
About Intellia Therapeutics
Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
Featured Story: What are Institutional Investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.